

Resource Summary Report

Generated by [ASWG](#) on Aug 5, 2026

ffpe

RRID:SCR_001307

Type: Tool

Proper Citation

ffpe (RRID:SCR_001307)

Resource Information

URL: <http://www.bioconductor.org/packages/release/bioc/html/ffpe.html>

Proper Citation: ffpe (RRID:SCR_001307)

Description: Software to identify low-quality data using metrics developed for expression data derived from Formalin-Fixed, Paraffin-Embedded (FFPE) data. Also a function for making Concordance at the Top plots (CAT-plots).

Abbreviations: ffpe

Synonyms: ffpe - Quality assessment and control for FFPE microarray expression data

Resource Type: software resource

Keywords: formalin-fixed, paraffin-embedded, gene expression, microarray, quality control, bio.tools

Availability: Free, Available for download, Freely available

Resource Name: ffpe

Resource ID: SCR_001307

Alternate IDs: OMICS_02026, biotools:ffpe

Alternate URLs: <https://bio.tools/ffpe>

License: GNU General Public License, v2 or newer

Record Creation Time: 20220129T080206+0000

Record Last Update: 20260801T190138+0000

Ratings and Alerts

No rating or validation information has been found for ffpe.

No alerts have been found for ffpe.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 496 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Yang J, et al. (2025) Transcriptomic Profiling and Tumor Microenvironment Classification Reveal Unique and Dynamic Immune Biology in HIV-Associated Kaposi Sarcoma. *Cells*, 14(2).

Xia L, et al. (2025) A whole-body imaging technique for tumor-specific diagnostics and screening of B7H3-targeted therapies. *The Journal of clinical investigation*, 135(6).

Xie M, et al. (2025) Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study. *Signal transduction and targeted therapy*, 10(1), 168.

Dev H, et al. (2025) Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(12), 2347.

Liu X, et al. (2025) Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis. *Signal transduction and targeted therapy*, 10(1), 237.

Geng J, et al. (2025) AI assistance enhances histopathologic distinction between sebaceous and squamous cell carcinoma of the eyelid. *NPJ digital medicine*, 8(1), 406.

Miyata H, et al. (2025) Localization of epidermal growth factor receptor-mutations using PNA:DNA probes in clinical specimens from patients with non-small cell lung cancer. *Scientific reports*, 15(1), 11314.

Sierra Roderio B, et al. (2025) Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial). *Oncoimmunology*, 14(1), 2513109.

Meireles SI, et al. (2025) Incidence of mycobacteria in pulmonary granulomatous lesions. *Clinics (Sao Paulo, Brazil)*, 80, 100564.

Wijaya LS, et al. (2025) Spatio-temporal transcriptomic analysis reveals distinct nephrotoxicity, DNA damage, and regeneration response after cisplatin. *Cell biology and toxicology*, 41(1), 49.

Cheng JJ, et al. (2025) Differential expression of CD175 and CA19-9 in pancreatic adenocarcinoma. *Scientific reports*, 15(1), 4177.

Legrand M, et al. (2025) Recurrent GRHL fusions in a subset of sebaceoma: microscopic and molecular characterisation of eight cases. *Histopathology*, 86(4), 571.

Vasuri F, et al. (2025) Beyond histology: A tissue algorithm predictive of post-surgical recurrence in hepatocellular carcinomas, including TERT promoter mutation. *Virchows Archiv : an international journal of pathology*, 486(2), 365.

Catapano F, et al. (2025) A comprehensive spatiotemporal map of dystrophin isoform expression in the developing and adult human brain. *Acta neuropathologica communications*, 13(1), 110.

Hollfoth V, et al. (2025) Accurate MS-Based Diagnostic Amyloid Typing Using Endogenously Normalized Protein Intensities in Formalin-Fixed Paraffin-Embedded Tissue. *Molecular & cellular proteomics : MCP*, 24(8), 101040.

Ding T, et al. (2025) A multimodal whole-slide foundation model for pathology. *Nature medicine*, 31(11), 3749.

Bignotti E, et al. (2025) TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study. *International journal of cancer*, 156(5), 1085.

Abuhussein O, et al. (2025) A Reflux Linked GATA Factor Fulcrum Dictates Lineage Commitment Through GPRC5B During the Esophageal Dysplastic Transition. *Cellular and molecular gastroenterology and hepatology*, 19(10), 101552.

Pavlířková K, et al. (2025) Correlation between p53 immunoexpression and TP53 mutation status in extrapulmonary small cell neuroendocrine carcinomas and its association with patient survival. *Virchows Archiv : an international journal of pathology*, 487(3), 557.

Palacios-Saucedo GDC, et al. (2025) Co-infection of human papillomavirus genotypes and Epstein-Barr virus in tumors of the oral cavity and oropharynx: a retrospective study in Northeastern Mexico. *IJID regions*, 14, 100555.